Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Oct 28, 2009; 15(40): 5058-5066
Published online Oct 28, 2009. doi: 10.3748/wjg.15.5058
Published online Oct 28, 2009. doi: 10.3748/wjg.15.5058
Table 1 Patient characteristics and UGT1A1 status (%)
| Total (n = 103) | WT (6/6) (n = 41) | (6/7) (n = 52) | (7/7) (n = 10) | |
| Age (yr) median (range) | 64 (41-79) | 63 (41-76) | 65 (42-79) | 65 (52-74) |
| Gender (M/F) | 70.5/29.5 | 70.7/29.3 | 67.3/32.7 | 80.0-20.0 |
| Colon cancer | 59.0 | 51.2 | 63.5 | 80.0 |
| Rectal cancer | 41.0 | 48.8 | 36.5 | 20.0 |
| Adjuvant pre-treatment | 35.2 | 43.9 | 30.8 | 20.0 |
| KPS 70%-90% | 43.8 | 29.3 | 51.9 | 70.0 |
| KPS 100% | 56.2 | 70.7 | 48.1 | 30.0 |
| LDH ≤ 240 U/L | 55.2 | 61.0 | 48.1 | 70.0 |
| LDH > 240 U/L | 44.8 | 39.0 | 51.9 | 30.0 |
-
Citation: Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ.
UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J Gastroenterol 2009; 15(40): 5058-5066 - URL: https://www.wjgnet.com/1007-9327/full/v15/i40/5058.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5058